In English | En español
Questions About Cancer? 1-800-4-CANCER

NCI Drug Dictionary


An orally bioavailable small molecule with potential antineoplastic activity. MET/VEGFR2 inhibitor GSK1363089 binds to and selectively inhibits hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), which may result in the inhibition of tumor angiogenesis, tumor cell proliferation and metastasis. The proto-oncogene c-MET has been found to be over-expressed in a variety of cancers. VEGFR2 is found on endothelial and hematopoietic cells and mediates the development of the vasculature and hematopoietic cells through VEGF signaling. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Code names:GSK1363089G
Chemical structures:1,1-cyclopropanedicarboxamide, N-[3-fluoro-4-([6-methody-7-[3-(4-morpholinyl)propoxy]-4-quinolinyl)oxy]phenyl]-N'-(4-fluorophenyl)